Calyx to scale up production, mulls IPO
This article was originally published in Scrip
Executive Summary
Calyx Chemicals and Pharmaceuticals, an Indian active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) firm, expects to invest about Rs1 billion ($22.5 million) to expand production capacities over the next few years.